A recent Epigen Biosciences Inc. patent describes ribosomal protein S6 kinase β (p70S6K) inhibitors reported to be useful for the treatment of diabetes, autism spectrum disorders, fibrosis, fragile X syndrome, liver diseases and nonalcoholic steatohepatitis (NASH).
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has developed antibody-drug conjugates (ADCs) consisting of 19F6_Hu35V1 antibody covalently linked to a cytotoxic drug through a linker.
Research at Silexon Biotech Co. Ltd. has led to the identification of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, hepatitis B virus, hepatitis C virus and HIV infections.
Several recent patents from Vertex Pharmaceuticals Inc. have disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, Charcot-Marie-tooth disease, cough, urinary incontinence and multiple sclerosis.
An Otsuka Pharmaceutical Co. Ltd. patent describes pyrazolo[1,5-a]pyrimidine lysophosphatidic acid receptor 2 (LPAR2; EDG4) antagonists reported to be useful for the treatment of atopic dermatitis, psoriasis, eczema, scleroderma and pruritus, among others.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified nitrogen-containing heterocyclic compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Innocure Therapeutics Inc. has synthesized piperidinedione derivatives acting as proteolysis targeting chimeric (PROTACs) compounds comprising an E3 ubiquitin ligase cereblon (CRBN) binding moiety covalently linked to hepatocyte growth factor receptor (HGFR; MET; c-MET)-targeting moiety via linker reported to be useful for the treatment of cancer.
Korean Research Institute of Bioscience and Biotechnology has described triterpenoid saponins isolated from Spinacia oleracea (spinach) reported to be useful for the treatment of inflammation.
Astex Therapeutics Ltd. and Taiho Pharmaceutical Co. Ltd. have divulged GTPase KRAS (G12C mutant), (G12D mutant) and/or (G12V mutant) inhibitors reported to be useful for the treatment of cancer.
RSS